Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo
Integra LifeSciences Corporation · Decision date Sep 18, 2026
What did the FDA decide?
P810006/S115 is a 30-Day Notice for the Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo, listed under product code LMF (absorbable hemostatic agent, collagen based) with Integra LifeSciences Corporation as applicant. The stated change is installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system, categorized as a process change involving manufacturer, sterilizer, packager, or supplier. The FDA database records the decision as OK30, dated 2026-09-18.
The identifier links this action to the original PMA P810006 as supplement S115, so it concerns that existing approval rather than a new approval of the whole system. The supplied statement does not specify which manufacturing site, what qualification criteria were used, or any resulting product or water-quality data, and it reports a purpose rather than demonstrating safety or clinical effectiveness. No new indication, trial, or clinical use is stated in the record.
FDA approval order statement
installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P810006/S115
- Regulatory pathway
- PMA supplement
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P810006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P810006 · Original PMA
COLLASTAT
P810006/S115 received
Application receipt date recorded by FDA.
P810006/S115 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P810006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P810006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COLLASTATP810006 | Integra LifeSciences Corporation | PMA approval | Dec 10, 1981 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Ferrosan Meidcal Devices A/S | PMA approval | Sep 30, 1999 | FDA | |
| Integra LifeSciences Corporation | PMA approval | Nov 8, 1985 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra LifeSciences Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 311 Enterprise Dr., Planisboro, NJ, 08536
Sources and methodology
- Original FDA record: P810006/S115
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

